T1	Participants 618 675	Children with National Cancer Institute standard-risk ALL
T2	Participants 535 616	1000 subjects that examined the efficacy of dexamethasone and IV 6-mercaptopurine
T3	Participants 92 148	patients with standard-risk acute lymphoblastic leukemia
